The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
Hosted on MSN1d
Biogen's Quarterly Earnings Preview: What You Need to KnowBiogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and ...
The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs ...
Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...
The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...
Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...
BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi: Stockholm Wednesday, January 15, 2025, 13:00 Hrs [IST] BioArctic AB (publ) announc ...
( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...
If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...
A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback